Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Blood Advances|January 9, 2025
Advancing drug development in myelodysplastic syndromesAlain Mina, Kathy L McGraw, Lea Cunningham, et al.
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.
Journal of the American Heart Association|May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid LeukemiaSruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic SyndromesAziz Nazha, Rami Komrokji, Manja Meggendorfer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2019
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with MyelofibrosisRoni Tamari, Franck Rapaport, Nan Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Blood Advances|January 9, 2025
Advancing drug development in myelodysplastic syndromesAlain Mina, Kathy L McGraw, Lea Cunningham, et al.
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.
Journal of the American Heart Association|May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid LeukemiaSruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic SyndromesAziz Nazha, Rami Komrokji, Manja Meggendorfer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2019
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with MyelofibrosisRoni Tamari, Franck Rapaport, Nan Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Pageof 13